As PD-1/PD-L1 immune checkpoint inhibitors are more frequently used in the treatment of NSCLC, a companion imaging methodology is becoming increasingly sought after for the staging and monitoring of patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.